test

Clinical Trials

Leukemia and Lymphoma

10
A Phase I Dose Finding Study of Belinostat plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients with Peripheral T Cell Lymphoma (PTCL)
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Principal Investigator: Madhav Dhodapkar
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
Disease/Condition: Cancer | Myeloid and Monocytic Leukemia
Principal Investigator: Nina Kadan-Lottick
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Disease/Condition: Leukemia, other
Principal Investigator: Steven Gore
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Disease/Condition: Leukemia, other
Principal Investigator: Steven Gore
A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Brentuximab Vedotin and CHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30- Positive Mature T-cell Lymphomas
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
AALL1231 -- A Phase III Randomized Trial Investigating Bortezomib (NSC#681239; IND#58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL_ and T-Lymphoblastic Lymphoma (T-LLy) -- A Groupwide Phase III Study
Principal Investigator: Nina Kadan-Lottick
An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Disease/Condition: Leukemia, not otherwise specified | Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Disease/Condition: Breast - Female | Lung | Ovary
Principal Investigator: Joseph Paul Eder
An Open-label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Disease/Condition: Leukemia, other
Principal Investigator: Nikolai Podoltsev
CPX-351 IN PATIENTS 60-75 YEARS OF AGE WITH AML
Disease/Condition: Leukemia, other
Principal Investigator: Nikolai Podoltsev
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Disease/Condition: Unknown Sites
Principal Investigator: Joseph Paul Eder
Newly Diagnosed High Risk B-Precursor ALL - Clofarabine
Disease/Condition: Leukemia, not otherwise specified
Principal Investigator: Nina Kadan-Lottick
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss